Research programme: membrane protein inhibitors - Daiichi Sankyo/Essential Therapeutics
Alternative Names: Efflux pump inhibitors research programme - Daiichi/Essential Therapeutics; MC 04112; MC 278537Latest Information Update: 25 Aug 2006
At a glance
- Originator Daiichi Sankyo Company; Essential Therapeutics [CEASED]
- Developer Daiichi Sankyo Company
- Class
- Mechanism of Action Membrane protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Pseudomonal infections
Most Recent Events
- 25 Aug 2006 Discontinued - Preclinical for Pseudomonal infections in Japan (unspecified route)
- 03 Apr 2006 Daiichi Pharmaceutical has merged with Sankyo to form Daiichi Sankyo Inc
- 04 Oct 2004 Essential Therapeutics has closed down